drugset

drugset / Trial / NCT01773174

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

NCT01773174 ↗

Phase 2 Withdrawn Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

Study will assess PK/PD parameters and safety and tolerability of the study medication in this age group

Timeline

Start: 2013-01
Primary completion: 2015-12
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran etexilate	Unknown	—	Oral

Indications